| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Véronique Ruppe, Pelin Dilsiz, Carol Shoshkes Reiss, Chad Carlson, Orrin Devinsky, David Zagzag, Howard L Weiner, Delia M Talo. Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia. vol 55. issue 4. 2014-06-30. PMID:24512506. |
genetic loss of tsc1/tsc2 function in tuberous sclerosis complex (tsc) results in altered mammalian target of rapamycin (mtor) signaling and abnormal brain development. |
2014-06-30 |
2023-08-12 |
Not clear |
| Ji-Young Ha, Ji-Soo Kim, Young-Hee Kang, Eugene Bok, Yoon-Seong Kim, Jin H So. Tnfaip8 l1/Oxi-β binds to FBXW5, increasing autophagy through activation of TSC2 in a Parkinson's disease model. Journal of neurochemistry. vol 129. issue 3. 2014-06-04. PMID:24444419. |
here, we demonstrate that the os-induced tnfaip8 l1/oxi-β could increase autophagy by a unique mechanism that increases the stability of tuberous sclerosis complex 2 (tsc2), a critical negative regulator of mtor. |
2014-06-04 |
2023-08-12 |
Not clear |
| Michael Cardamone, Danny Flanagan, David Mowat, Sean E Kennedy, Maya Chopra, John A Lawso. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. The Journal of pediatrics. vol 164. issue 5. 2014-06-02. PMID:24518170. |
to evaluate the efficacy and side effects of oral mammalian target of rapamycin (mtor) inhibitors in children and adolescents with tuberous sclerosis complex (tsc) and intractable epilepsy or subependymal giant cell astrocytoma (sega). |
2014-06-02 |
2023-08-12 |
Not clear |
| Jinhong Wu, Jialong Yang, Kai Yang, Hongxia Wang, Balachandra Gorentla, Jinwook Shin, Yurong Qiu, Loretta G Que, W Michael Foster, Zhenwei Xia, Hongbo Chi, Xiao-Ping Zhon. iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions. The Journal of clinical investigation. vol 124. issue 4. 2014-06-02. PMID:24614103. |
the tumor suppressor tuberous sclerosis 1 (tsc1) is an important negative regulator of mtor signaling, which regulates t cell differentiation, function, and trafficking. |
2014-06-02 |
2023-08-12 |
mouse |
| Jinhong Wu, Jinwook Shin, Danli Xie, Hongxia Wang, Jimin Gao, Xiao-Ping Zhon. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. Journal of immunology (Baltimore, Md. : 1950). vol 192. issue 6. 2014-05-15. PMID:24532578. |
we report in this study that the tuberous sclerosis 1 (tsc1), a negative regulator of mtor signaling, plays a crucial role in inkt cell anergy. |
2014-05-15 |
2023-08-12 |
Not clear |
| Mary E Peterso. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. vol 21. issue 8. 2014-05-13. PMID:23686401. |
everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
2014-05-13 |
2023-08-12 |
Not clear |
| Zhenguo Chen, Heling Dong, Chunhong Jia, Qiancheng Song, Juan Chen, Yue Zhang, Pinglin Lai, Xiaorong Fan, Xuan Zhou, Miao Liu, Jun Lin, Cuilan Yang, Ming Li, Tianming Gao, Xiaochun Ba. Activation of mTORC1 in collecting ducts causes hyperkalemia. Journal of the American Society of Nephrology : JASN. vol 25. issue 3. 2014-05-08. PMID:24203997. |
mutation of tsc (encoding tuberous sclerosis complex protein) and activation of mammalian target of rapamycin (mtor) have been implicated in the pathogenesis of several renal diseases, such as diabetic nephropathy and polycystic kidney disease. |
2014-05-08 |
2023-08-12 |
mouse |
| Yanan Guo, David J Kwiatkowsk. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Molecular cancer research : MCR. vol 11. issue 5. 2014-05-02. PMID:23386687. |
equivalent benefit of rapamycin and a potent mtor atp-competitive inhibitor, mln0128 (ink128), in a mouse model of tuberous sclerosis. |
2014-05-02 |
2023-08-12 |
mouse |
| Laura Magri, Manuela Cominelli, Marco Cambiaghi, Marco Cursi, Letizia Leocani, Fabio Minicucci, Pietro Luigi Poliani, Rossella Gall. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models. Disease models & mechanisms. vol 6. issue 5. 2014-04-22. PMID:23744272. |
timing of mtor activation affects tuberous sclerosis complex neuropathology in mouse models. |
2014-04-22 |
2023-08-12 |
mouse |
| Esther Lopez-Rivera, Padmini Jayaraman, Falguni Parikh, Michael A Davies, Suhendan Ekmekcioglu, Sudeh Izadmehr, Denái R Milton, Jerry E Chipuk, Elizabeth A Grimm, Yeriel Estrada, Julio Aguirre-Ghiso, Andrew G Sikor. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer research. vol 74. issue 4. 2014-04-22. PMID:24398473. |
inos expression and no were associated with reversible nitrosylation of tuberous sclerosis complex (tsc) 2, and inhibited dimerization of tsc2 with its inhibitory partner tsc1, enhancing gtpase activity of its target ras homolog enriched in brain (rheb), a critical activator of mtor signaling. |
2014-04-22 |
2023-08-12 |
human |
| Elizabeth P Henske, Rebekah Rasooly, Brian Siroky, John Bissle. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. American journal of physiology. Renal physiology. vol 306. issue 3. 2014-04-08. PMID:24226526. |
tuberous sclerosis complex, mtor, and the kidney: report of an niddk-sponsored workshop. |
2014-04-08 |
2023-08-12 |
Not clear |
| Elizabeth P Henske, Rebekah Rasooly, Brian Siroky, John Bissle. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. American journal of physiology. Renal physiology. vol 306. issue 3. 2014-04-08. PMID:24226526. |
many of these advances originated from studies of the genetic disease tuberous sclerosis complex (tsc), leading to one of the clearest therapeutic opportunities to target mtor with rapamycin and its analogs ("rapalogs"), which effectively inhibit mtor complex 1 (mtorc1) by an allosteric mechanism. |
2014-04-08 |
2023-08-12 |
Not clear |
| Katarzyna Kotulska, Dariusz Chmielewski, Julita Borkowska, Elżbieta Jurkiewicz, Dariusz Kuczyński, Tomasz Kmieć, Barbara Łojszczyk, Dorota Dunin-Wąsowicz, Sergiusz Jóźwia. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 17. issue 5. 2014-04-03. PMID:23567018. |
tuberous sclerosis complex (tsc) is a genetic disorder characterized by increased mammalian target of rapamycin (mtor) activation and growth of benign tumors in several organs throughout the body. |
2014-04-03 |
2023-08-12 |
Not clear |
| Brittany L Jacobs, Jae-Sung You, John W Frey, Craig A Goodman, David M Gundermann, Troy A Hornberge. Eccentric contractions increase the phosphorylation of tuberous sclerosis complex-2 (TSC2) and alter the targeting of TSC2 and the mechanistic target of rapamycin to the lysosome. The Journal of physiology. vol 591. issue 18. 2014-04-03. PMID:23732640. |
the goal of this study was to determine whether the mechanical activation of mechanistic target of rapamycin (mtor) signalling is associated with changes in phosphorylation of tuberous sclerosis complex-2 (tsc2) and targeting of mtor and tsc2 to the lysosome. |
2014-04-03 |
2023-08-12 |
mouse |
| John Kenneth Schoolmeester, Brooke E Howitt, Michelle S Hirsch, Paola Dal Cin, Bradley J Quade, Marisa R Nucc. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. The American journal of surgical pathology. vol 38. issue 2. 2014-03-06. PMID:24418852. |
recent studies have shown that sporadic and tuberous sclerosis complex-associated pecoma may respond to mtor inhibitors underscoring the importance of recognizing this tumor. |
2014-03-06 |
2023-08-12 |
Not clear |
| Laura Magri, Rossella Gall. mTOR signaling in neural stem cells: from basic biology to disease. Cellular and molecular life sciences : CMLS. vol 70. issue 16. 2014-02-06. PMID:23124271. |
the mammalian target of rapamycin (mtor) pathway is a central controller of growth and homeostasis, and, as such, is implicated in disease states where growth is deregulated, namely cancer, metabolic diseases, and hamartoma syndromes like tuberous sclerosis complex (tsc). |
2014-02-06 |
2023-08-12 |
Not clear |
| Yoon Park, Hyung-Seung Jin, Justine Lopez, Chris Elly, Gisen Kim, Masako Murai, Mitchell Kronenberg, Yun-Cai Li. TSC1 regulates the balance between effector and regulatory T cells. The Journal of clinical investigation. vol 123. issue 12. 2014-02-04. PMID:24270422. |
we found that t cell-specific deletion of the gene encoding tuberous sclerosis 1 (tsc1), an upstream negative regulator of mtor, resulted in augmented th1 and th17 differentiation and led to severe intestinal inflammation in a colitis model. |
2014-02-04 |
2023-08-12 |
Not clear |
| Altaf Mohammed, Naveena B Janakiram, Misty Brewer, Rebekah L Ritchie, Anuj Marya, Stan Lightfoot, Vernon E Steele, Chinthalapally V Ra. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Translational oncology. vol 6. issue 6. 2014-01-27. PMID:24466367. |
the pancreatic tissue and/or serum of mice fed metformin showed a significant inhibition of mammalian target of rapamycin (mtor), extracellular signal-regulated kinases (erk), phosphorylated extracellular signal-regulated kinases (perk), and insulin-like growth factor 1 (igf-1) with an increase in phosphorylated 5' adenosine monophosphate kinase (pampk), tuberous sclerosis complex 1 (tsc1, tsc2), c-protein and an autophagy related protein 2 (atg2). |
2014-01-27 |
2023-08-12 |
mouse |
| Paolo Curatolo, Romina Moaver. mTOR inhibitors as a new therapeutic option for epilepsy. Expert review of neurotherapeutics. vol 13. issue 6. 2014-01-09. PMID:23739000. |
dysregulation of the mtor signaling pathway is associated with highly epileptogenic conditions such as tuberous sclerosis, focal cortical dysplasia, hemimegalencephaly and ganglioglioma, grouped under the term of 'mtoropathies'. |
2014-01-09 |
2023-08-12 |
Not clear |
| Paolo Curatolo, Romina Moaver. mTOR inhibitors as a new therapeutic option for epilepsy. Expert review of neurotherapeutics. vol 13. issue 6. 2014-01-09. PMID:23739000. |
preliminary studies in patients affected by tuberous sclerosis and treated with rapamycin or everolimus demonstrated potential benefits in seizure frequency reduction, suggesting that mtor inhibition could be a promising treatment option for mtoropathies-related epilepsy. |
2014-01-09 |
2023-08-12 |
Not clear |